1	SENATE FLOOR VERSION
2	April 12, 2023 AS AMENDED
3	ENGROSSED HOUSE BILL NO. 2748 By: Miller, Conley, West (Tammy), Hasenbeck, Stark,
5	Townley, Roe, Baker, Provenzano, Munson, Crosswhite Hader, Hefner, Schreiber, Ranson, Goodwin,
7	and Fugate of the House
8	and
9	Stanley of the Senate
LO	
11	[public health and safety - step therapy
L2	requirements - coverage - effective date]
13	
L 4	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
L5	SECTION 1. NEW LAW A new section of law to be codified
L 6	in the Oklahoma Statutes as Section 7320 of Title 63, unless there
L7	is created a duplication in numbering, reads as follows:
L8	For the purpose of prohibiting step therapy requirements for
L 9	certain prescription drugs to treat advanced metastatic cancer and
20	associated conditions.
21	As used in this section:
22	1. "Associated conditions" means the symptoms or side effects
23	associated with advanced metastatic cancer or its treatment and
ΣД	

- which, in the judgment of the health care practitioner, will further jeopardize the health of a patient if left untreated;
 - 2. "Advanced metastatic cancer" means cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other areas or parts of the body.
- SECTION 2. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 7321 of Title 63, unless there is created a duplication in numbering, reads as follows:
 - A. A health benefit plan that provides coverage for advanced metastatic cancer and associated conditions may not require, before the health benefit plan provides coverage of a prescription drug approved by the United States Food and Drug Administration, that the enrollee:
 - 1. Fails to successfully respond to a different drug; or
 - 2. Proves a history of failure of a different drug.
 - B. This section applies only to a drug, the use of which is:
- 1. Consistent with best practices for the treatment of advanced metastatic cancer or an associated condition;
 - 2. Supported by peer-reviewed, evidence-based literature; and
 - 3. Approved by the United States Food and Drug Administration.
- 21 SECTION 3. This act shall become effective November 1, 2023.
- 22 COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS
 April 12, 2023 DO PASS AS AMENDED

23

3

4

5

9

10

11

12

13

14

15

16

19

20

24